HB0030 / Zhejiang Huahai Pharma - LARVOL DELTA

Huahai Pharmaceutical (600521.SH): HB0025 Injection Combined with HB0030 Injection Obtained Drug Clinical Trial License [Google translation] (Zhitong Finance) - "Zhitong Finance APP news, Huahai Pharmaceutical...announced that the company's subsidiaries Shanghai Huaaotai Biopharmaceutical Co., Ltd. and Huabo Biomedical Technology (Shanghai) Co., Ltd. Food and Drug Administration) approved HB0025 injection combined with HB0030 injection for the treatment of advanced non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), colorectal cancer (CRC) and other types of advanced solid tumors 'drug clinical trial approval Notice'."

New trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A phase Ia trial to evaluate the safety and efficacy of HB0030, an anti-TIGIT antibody, in patients with advanced solid tumors: Preliminary results. (ASCO 2023) - P1 | "HB0030 showed very well safety in the stage of dose escalation from 0.1 to 20 mg/kg, and potential promising anti-tumor activity above 3mg/kg dose in advanced solid tumors pts, especially in NSCLC. Currently, 30mg/kg and 40mg/kg dose escalation are ongoing. Clinical trial information: NCT05706207."

Clinical • IO biomarker • Metastases • P1 data • Anemia • Cardiovascular • Cervical Cancer • Hematological Disorders • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • TIGIT • TP53

Hua Ao Tai, a subsidiary of Huahai Pharmaceutical (600521.SH), obtained the drug clinical trial license [Google translation] (Zhitong Finance) - "Zhitong Finance APP news, Huahai Pharmaceutical...announced that the company's subsidiary Shanghai Huaaotai Biopharmaceutical Co., Ltd. Approved the New Drug Clinical Trial (IND) application for a phase Ib/II study of HB0025 injection combined with HB0030 injection in patients with advanced solid tumors."

IND • Oncology • Solid Tumor

A Study of HB0030 Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Huabo Biopharm Co., Ltd.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor

Inxmed collaborates with Huaota to develop combination therapy for solid tumors (Bioworld) - "Inxmed Co. Ltd. has formed a partnership with Shanghai Huaota Biopharmaceutical Co. Ltd. to combine the former’s IN-10018 and the latter’s HB-0030 for the treatment of solid tumors by jointly running preclinical studies and clinical trials."

Licensing / partnership • Oncology • Solid Tumor